^
Association details:
| Biomarker: | Chr t(11;14) + BCL2 : BCL2L1 ratio elevation |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
VENETOCLAX MONOTHERAPY AND COMBINED WITH DEXAMETHASONE AS TARGETED THERAPY FOR RELAPSED/REFRACTORY T(11;14) MULTIPLE MYELOMA
Published date:
05/17/2018
Excerpt:
...50 pts enrolled with t(11;14)...pts received Ven once daily as monotherapy (n=30; 300, 600, 900, 1200mg) or Ven 800mg + Dex 40mg (n=20)....response to Ven monotherapy was associated with a higher BCL2:BCL2L1 gene expression ratio and improved ORR (high vs low ratio: 89% vs 27%).
